UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

RET rearrangements are actionable alterations in breast cancer

Nature communications, 2018-11, Vol.9 (1), p.4821-13, Article 4821

2018

Volltextzugriff (PDF)

The metabolic demands of cancer cells are coupled to their size and protein synthesis rates

Cancer & metabolism, 2013-11, Vol.1 (1), p.20-20, Article 20

2013

Volltextzugriff (PDF)

Metabotropic glutamate receptor 1 expression and its polymorphic variants associate with breast cancer phenotypes

PloS one, 2013-07, Vol.8 (7), p.e69851

2013

Volltextzugriff (PDF)

Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands

Frontiers in immunology, 2023-09, Vol.14, p.1151748-1151748

2023

Volltextzugriff (PDF)

Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells

Breast cancer research and treatment, 2015-05, Vol.151 (1), p.57-73

2015

Volltextzugriff (PDF)

Riluzole exerts distinct antitumor effects from a metabotropic glutamate receptor 1-specific inhibitor on breast cancer cells

Oncotarget, 2017-07, Vol.8 (27), p.44639-44653

2017

Volltextzugriff (PDF)

Fulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugs

Cancer letters, 2014-08, Vol.350 (1), p.52-60

2014

Volltextzugriff (PDF)

Inhibitory Effects of Different Forms of Tocopherols, Tocopherol Phosphates, and Tocopherol Quinones on Growth of Colon Cancer Cells

Journal of agricultural and food chemistry, 2013-09, Vol.61 (36), p.8533-8540

2013

Volltextzugriff (PDF)

624 Longitudinal scRNAseq profiling of PBMCs from melanoma patients treated with anti-CTLA4 or anti-PD1/CTLA4 combination elucidates mechanisms of immunotherapy resistance

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A711-A712

2023

Volltextzugriff (PDF)

P53 regulates the migration of mesenchymal stromal cells in response to the tumor microenvironment through both CXCL12-dependent and -independent mechanisms

International journal of oncology, 2013-12, Vol.43 (6), p.1817-1823

2013

Volltextzugriff (PDF)

The role of chromodomain helicase DNA binding protein 1 (CHD1) in promoting an invasive prostate cancer phenotype

Therapeutic advances in urology, 2021, Vol.13, p.17562872211022462-17562872211022462

2021

Volltextzugriff (PDF)

Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other Cancers

Biomarkers in Cancer, 2016-01, Vol.2016 (Suppl. 1), p.1-14

2016

Volltextzugriff (PDF)

Role of Biomarkers in the Development of PARP Inhibitors

Biomarkers in Cancer, 2016-01, Vol.2016 (Suppl. 1), p.15-25

2016

Volltextzugriff (PDF)

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial

Journal of clinical oncology, 2023-05, Vol.41 (15), p.2724-2735

2023

Volltextzugriff (PDF)

Association of circulating tumor DNA kinetics with disease recurrence in patients with stage IIIB/C/IV melanoma treated with adjuvant immunotherapy in Checkmate 238

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9577-9577

2023

Volltextzugriff (PDF)

Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma

Clinical cancer research, 2024-10, Vol.30 (19), p.4412-4423

2024

Volltextzugriff (PDF)

Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): Overall survival (OS) and melanoma-specific survival (MSS) outcomes at 3 years

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.9524-9524

2024

Volltextzugriff (PDF)

Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9502-9502

2023

Volltextzugriff (PDF)

Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9504-9504

2023

Volltextzugriff (PDF)

Abstract 2487: Functional characterization of the BRCA2 variant, K3326X

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.2487-2487

2017

Volltextzugriff (PDF)

Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9505-9505

2022

Volltextzugriff (PDF)

Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047)

Journal of clinical oncology, 2022-04, Vol.40 (36_suppl), p.360385-360385

2022

Volltextzugriff (PDF)

CheckMate 8KX: Phase 1/2 multitumor preliminary analyses of a subcutaneous formulation of nivolumab (± rHuPH20)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2575-2575

2021

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(41)

Sprache

Englisch
(41)

Erscheinungsjahr

n.n

Thema

Science & Technology
(17)
Life Sciences & Biomedicine
(14)
Humans
(10)
Oncology
(9)
Breast Cancer
(7)
Animals
(5)
Female
(5)
Breast Neoplasms - Genetics
(4)
Cell Biology
(4)
Cell Line, Tumor
(4)
Gene Expression
(4)
Melanoma
(4)
Antineoplastic Agents - Pharmacology
(3)
Biological And Medical Sciences
(3)
Biology
(3)
Breast Neoplasms - Drug Therapy
(3)
Breast Neoplasms - Pathology
(3)
Cancer
(3)
Cell Cycle
(3)
Cell Proliferation - Drug Effects
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

RET rearrangements are actionable alterations in breast cancer

The metabolic demands of cancer cells are coupled to their size and protein synthesis rates

Metabotropic glutamate receptor 1 expression and its polymorphic variants associate with breast cancer phenotypes

Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands

Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells

Riluzole exerts distinct antitumor effects from a metabotropic glutamate receptor 1-specific inhibitor on breast cancer cells

Fulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugs

Inhibitory Effects of Different Forms of Tocopherols, Tocopherol Phosphates, and Tocopherol Quinones on Growth of Colon Cancer Cells

624 Longitudinal scRNAseq profiling of PBMCs from melanoma patients treated with anti-CTLA4 or anti-PD1/CTLA4 combination elucidates mechanisms of immunotherapy resistance

P53 regulates the migration of mesenchymal stromal cells in response to the tumor microenvironment through both CXCL12-dependent and -independent mechanisms

The role of chromodomain helicase DNA binding protein 1 (CHD1) in promoting an invasive prostate cancer phenotype

A functionally significant SNP in TP53 and breast cancer risk in African-American women

Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other Cancers

Role of Biomarkers in the Development of PARP Inhibitors

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

Association of circulating tumor DNA kinetics with disease recurrence in patients with stage IIIB/C/IV melanoma treated with adjuvant immunotherapy in Checkmate 238

Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma

Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): Overall survival (OS) and melanoma-specific survival (MSS) outcomes at 3 years

Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047

Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K)

Abstract 2487: Functional characterization of the BRCA2 variant, K3326X

Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047

Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047)

CheckMate 8KX: Phase 1/2 multitumor preliminary analyses of a subcutaneous formulation of nivolumab (± rHuPH20)

Suchergebnisse filtern